CN110403966A - Radix Angelicae Sinensis notoginseng composition and its purposes in adjusting enteric microorganism - Google Patents
Radix Angelicae Sinensis notoginseng composition and its purposes in adjusting enteric microorganism Download PDFInfo
- Publication number
- CN110403966A CN110403966A CN201810400384.4A CN201810400384A CN110403966A CN 110403966 A CN110403966 A CN 110403966A CN 201810400384 A CN201810400384 A CN 201810400384A CN 110403966 A CN110403966 A CN 110403966A
- Authority
- CN
- China
- Prior art keywords
- pseudomonas
- chinese medicine
- medicine composition
- enteric microorganism
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 71
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 244000005700 microbiome Species 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 241000589516 Pseudomonas Species 0.000 claims description 34
- 241000894006 Bacteria Species 0.000 claims description 28
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 20
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 15
- 241000194017 Streptococcus Species 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 241000194033 Enterococcus Species 0.000 claims description 11
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 229940039696 lactobacillus Drugs 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 230000000968 intestinal effect Effects 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 7
- 241001515965 unidentified phage Species 0.000 claims description 7
- 241000606125 Bacteroides Species 0.000 claims description 6
- 241000588807 Bordetella Species 0.000 claims description 6
- 241000605902 Butyrivibrio Species 0.000 claims description 6
- 241000588914 Enterobacter Species 0.000 claims description 6
- 241000589565 Flavobacterium Species 0.000 claims description 6
- 241000607768 Shigella Species 0.000 claims description 6
- 241000187747 Streptomyces Species 0.000 claims description 6
- 241000589886 Treponema Species 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 241000605894 Porphyromonas Species 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 241000589291 Acinetobacter Species 0.000 claims description 4
- 241000186146 Brevibacterium Species 0.000 claims description 4
- 241001453380 Burkholderia Species 0.000 claims description 4
- 241000611330 Chryseobacterium Species 0.000 claims description 4
- 206010010774 Constipation Diseases 0.000 claims description 4
- 241000305071 Enterobacterales Species 0.000 claims description 4
- 241000588722 Escherichia Species 0.000 claims description 4
- 241000605909 Fusobacterium Species 0.000 claims description 4
- 241000588748 Klebsiella Species 0.000 claims description 4
- 241000160321 Parabacteroides Species 0.000 claims description 4
- 241000589180 Rhizobium Species 0.000 claims description 4
- 241001136275 Sphingobacterium Species 0.000 claims description 4
- 241000736131 Sphingomonas Species 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 241000190890 Capnocytophaga Species 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 241000588877 Eikenella Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 241000605036 Selenomonas Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 241000187643 Amycolatopsis Species 0.000 claims description 2
- 241000204018 Anaeroplasma Species 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 241000186321 Cellulomonas Species 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 241001478240 Coccus Species 0.000 claims description 2
- 241001464948 Coprococcus Species 0.000 claims description 2
- 241000970818 Cyclobacterium Species 0.000 claims description 2
- 241000605898 Fibrobacter Species 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 2
- 241000589989 Helicobacter Species 0.000 claims description 2
- 208000000913 Kidney Calculi Diseases 0.000 claims description 2
- 241000568397 Lysinibacillus Species 0.000 claims description 2
- 241000202987 Methanobrevibacter Species 0.000 claims description 2
- 241000204677 Methanosphaera Species 0.000 claims description 2
- 241000589350 Methylobacter Species 0.000 claims description 2
- 241000589323 Methylobacterium Species 0.000 claims description 2
- 241000158644 Muricauda Species 0.000 claims description 2
- 241001291960 Myroides Species 0.000 claims description 2
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 241001660097 Pedobacter Species 0.000 claims description 2
- 241000192696 Porphyrobacter Species 0.000 claims description 2
- 241000605861 Prevotella Species 0.000 claims description 2
- 241001660099 Sphingobacteriaceae Species 0.000 claims description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 claims description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 claims description 2
- 241000864375 Sulfitobacter Species 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 2
- 241000123710 Sutterella Species 0.000 claims description 2
- 241000186339 Thermoanaerobacter Species 0.000 claims description 2
- 241000202898 Ureaplasma Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 230000000696 methanogenic effect Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 241000588921 Enterobacteriaceae Species 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 239000000284 extract Substances 0.000 description 30
- 239000000843 powder Substances 0.000 description 27
- 241000125175 Angelica Species 0.000 description 26
- 235000001287 Guettarda speciosa Nutrition 0.000 description 26
- 238000001035 drying Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000001179 sorption measurement Methods 0.000 description 9
- 238000010025 steaming Methods 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000000638 solvent extraction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241000792859 Enema Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000007920 enema Substances 0.000 description 6
- 229940095399 enema Drugs 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000004042 decolorization Methods 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 241000360099 Clostridium gasigenes Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- 241000731710 Allobaculum Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001140793 Bacteroides caecimuris Species 0.000 description 1
- 241001032450 Bacteroides cellulosilyticus Species 0.000 description 1
- 241001135322 Bacteroides eggerthii Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000168642 Bacteroides gallinarum Species 0.000 description 1
- 241001221145 Bacteroides pyogenes Species 0.000 description 1
- 241001122267 Bacteroides salyersiae Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 241000084800 Bacteroides sp. 14(A) Species 0.000 description 1
- 241001208820 Bacteroides sp. 2_1_16 Species 0.000 description 1
- 241000817464 Bacteroides sp. 3_1_13 Species 0.000 description 1
- 241001208871 Bacteroides sp. 3_1_19 Species 0.000 description 1
- 241000817514 Bacteroides sp. 3_1_23 Species 0.000 description 1
- 241001208868 Bacteroides sp. 3_1_40A Species 0.000 description 1
- 241000817512 Bacteroides sp. 3_2_5 Species 0.000 description 1
- 241000333180 Bacteroides sp. AR29 Species 0.000 description 1
- 241001118940 Bacteroides sp. An269 Species 0.000 description 1
- 241000115153 Bacteroides xylanisolvens Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 241001313857 Bletilla striata Species 0.000 description 1
- 241001216243 Butyricimonas Species 0.000 description 1
- 241000193174 Butyrivibrio crossotus Species 0.000 description 1
- 241000501845 Butyrivibrio sp. AD3002 Species 0.000 description 1
- 241000392938 Butyrivibrio sp. AE2005 Species 0.000 description 1
- 241000763063 Butyrivibrio sp. INlla14 Species 0.000 description 1
- 241000501865 Butyrivibrio sp. LC3010 Species 0.000 description 1
- 241000689642 Butyrivibrio sp. NC2002 Species 0.000 description 1
- 241000501869 Butyrivibrio sp. NC2007 Species 0.000 description 1
- 241000501867 Butyrivibrio sp. NC3005 Species 0.000 description 1
- 241000502041 Butyrivibrio sp. VCD2006 Species 0.000 description 1
- 241000689614 Butyrivibrio sp. WCE2006 Species 0.000 description 1
- 241000763115 Butyrivibrio sp. YAB3001 Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000186542 Clostridium baratii Species 0.000 description 1
- 241001335108 Clostridium bornimense Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000779795 Clostridium cavendishii Species 0.000 description 1
- 241001509496 Clostridium celatum Species 0.000 description 1
- 241000193169 Clostridium cellulovorans Species 0.000 description 1
- 241000206044 Clostridium chauvoei Species 0.000 description 1
- 241000193167 Clostridium cochlearium Species 0.000 description 1
- 241001147788 Clostridium collagenovorans Species 0.000 description 1
- 241001660538 Clostridium frigidicarnis Species 0.000 description 1
- 241000123594 Clostridium grantii Species 0.000 description 1
- 241000779784 Clostridium hydrogeniformans Species 0.000 description 1
- 241000977660 Clostridium neonatale Species 0.000 description 1
- 241000744741 Clostridium saudiense Species 0.000 description 1
- 241000193466 Clostridium septicum Species 0.000 description 1
- 241000706512 Clostridium sp. Bc-iso-3 Species 0.000 description 1
- 241000023155 Clostridium sp. DSM 8431 Species 0.000 description 1
- 241001315222 Clostridium sp. HMSC19B04 Species 0.000 description 1
- 241001315223 Clostridium sp. HMSC19C08 Species 0.000 description 1
- 241001315304 Clostridium sp. HMSC19D07 Species 0.000 description 1
- 241000996183 Clostridium sp. KNHs209 Species 0.000 description 1
- 241000515543 Clostridium sp. ND2 Species 0.000 description 1
- 241000962926 Clostridium sp. SS2/1 Species 0.000 description 1
- 241000431362 Clostridium sp. USBA 49 Species 0.000 description 1
- 241000516778 Clostridium sp. mt5 Species 0.000 description 1
- 241000881337 Clostridium taeniosporum Species 0.000 description 1
- 241000186520 Clostridium tetanomorphum Species 0.000 description 1
- 241000264391 Clostridium uliginosum Species 0.000 description 1
- 241000192020 Clostridium ventriculi Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000605056 Cytophaga Species 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241001069070 Enterobacter sp. BIDMC94 Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241001007232 Enterococcus phage vB_EfaP_IME195 Species 0.000 description 1
- 241001561189 Enterococcus sp. HMSC074F07 Species 0.000 description 1
- 241000930781 Flavobacterium akiainvivens Species 0.000 description 1
- 241000335416 Flavobacterium frigoris Species 0.000 description 1
- 241001240315 Flavobacterium indicum Species 0.000 description 1
- 241000605108 Flavobacterium johnsoniae Species 0.000 description 1
- 241001474354 Flavobacterium marinum Species 0.000 description 1
- 241001447185 Flavobacterium sp. 316 Species 0.000 description 1
- 241000421036 Flavobacterium sp. A45 Species 0.000 description 1
- 241000601735 Flavobacterium terrigena Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 241001503513 Helicobacter bilis Species 0.000 description 1
- 241000590010 Helicobacter fennelliae Species 0.000 description 1
- 241000008151 Helicobacter himalayensis Species 0.000 description 1
- 241000944308 Helicobacter macacae Species 0.000 description 1
- 241001496695 Helicobacter magdeburgensis Species 0.000 description 1
- 241001620783 Helicobacter saguini Species 0.000 description 1
- 241000589999 Helicobacter sp. CLO-3 Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241001386813 Kraken Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 241001108870 Lactobacillus kimchicus Species 0.000 description 1
- 241000394636 Lactobacillus mucosae Species 0.000 description 1
- 241000216456 Lactobacillus panis Species 0.000 description 1
- 241001520501 Lactobacillus pentosiphilus Species 0.000 description 1
- 241001495404 Lactobacillus pontis Species 0.000 description 1
- 241001331597 Lactobacillus sp. Marseille-P3519 Species 0.000 description 1
- 241000642025 Lactobacillus sp. UMNPBX12 Species 0.000 description 1
- 241000642043 Lactobacillus sp. UMNPBX5 Species 0.000 description 1
- 241000642029 Lactobacillus sp. UMNPBX8 Species 0.000 description 1
- 241000186783 Lactobacillus vaginalis Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001531418 Methanobrevibacter arboriphilus Species 0.000 description 1
- 241000244328 Methanobrevibacter curvatus Species 0.000 description 1
- 241000544893 Methanobrevibacter filiformis Species 0.000 description 1
- 241001407720 Methanobrevibacter gottschalkii Species 0.000 description 1
- 241000586182 Methanobrevibacter millerae Species 0.000 description 1
- 241001160906 Methanobrevibacter olleyae Species 0.000 description 1
- 241000936900 Methanobrevibacter oralis Species 0.000 description 1
- 241001648836 Methanobrevibacter ruminantium Species 0.000 description 1
- 241000202985 Methanobrevibacter smithii Species 0.000 description 1
- 241000554923 Methanobrevibacter sp. 87.7 Species 0.000 description 1
- 241001363507 Methanobrevibacter sp. A27 Species 0.000 description 1
- 241001363690 Methanobrevibacter sp. A54 Species 0.000 description 1
- 241001530312 Methanobrevibacter sp. YE315 Species 0.000 description 1
- 241001407719 Methanobrevibacter wolinii Species 0.000 description 1
- 241000781379 Methanosphaera cuniculi Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 241001575208 Paenibacillus sp. RUD330 Species 0.000 description 1
- 241001276286 Paenibacillus sp. St-s Species 0.000 description 1
- 241000072244 Paenibacillus sp. UNC496MF Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 241000262693 Parabacteroides sp. D25 Species 0.000 description 1
- 241000296520 Parabacteroides sp. YL27 Species 0.000 description 1
- 241001347409 Pedobacter ginsenosidimutans Species 0.000 description 1
- 241001032431 Pedobacter himalayensis Species 0.000 description 1
- 241001550228 Pedobacter nyackensis Species 0.000 description 1
- 241001135211 Porphyromonas asaccharolytica Species 0.000 description 1
- 241001509393 Porphyromonas cangingivalis Species 0.000 description 1
- 241001509390 Porphyromonas canoris Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000095441 Porphyromonas gingivicanis Species 0.000 description 1
- 241001185171 Porphyromonas sp. COT-108 OH1349 Species 0.000 description 1
- 241000462030 Porphyromonas sp. COT-108 OH2963 Species 0.000 description 1
- 241000838798 Porphyromonas sp. KLE 1280 Species 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 241001343452 Pseudomonas otitidis Species 0.000 description 1
- 241000467496 Pseudomonas protegens Species 0.000 description 1
- 241000389687 Pseudomonas sp. Bc-h Species 0.000 description 1
- 240000005893 Pteridium aquilinum Species 0.000 description 1
- 235000009936 Pteridium aquilinum Nutrition 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 241001225260 Shigella sp. PAMC 28760 Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241000302473 Streptococcus sp. CM7 Species 0.000 description 1
- 241000165517 Streptococcus sp. GMD6S Species 0.000 description 1
- 241001561720 Streptococcus sp. HMSC034B04 Species 0.000 description 1
- 241001561245 Streptococcus sp. HMSC034E12 Species 0.000 description 1
- 241000667575 Streptococcus sp. HMSC056C01 Species 0.000 description 1
- 241001561249 Streptococcus sp. HMSC056D01 Species 0.000 description 1
- 241001562158 Streptococcus sp. HMSC064H02 Species 0.000 description 1
- 241000667298 Streptococcus sp. HMSC071H03 Species 0.000 description 1
- 241001561750 Streptococcus sp. HMSC072G02 Species 0.000 description 1
- 241001561734 Streptococcus sp. HMSC074F09 Species 0.000 description 1
- 241000667716 Streptococcus sp. HMSC076H07 Species 0.000 description 1
- 241000667567 Streptococcus sp. HMSC076H08 Species 0.000 description 1
- 241001561943 Streptococcus sp. HMSC078E03 Species 0.000 description 1
- 241001562203 Streptococcus sp. HMSC078E08 Species 0.000 description 1
- 241000596534 Streptococcus virus C1 Species 0.000 description 1
- 241000187419 Streptomyces rimosus Species 0.000 description 1
- 241000267321 Streptomyces sp. AA4 Species 0.000 description 1
- 241000907463 Streptomyces sp. NRRL F-5639 Species 0.000 description 1
- 241000907453 Streptomyces sp. NRRL F-6676 Species 0.000 description 1
- 241000511798 Streptomyces sp. NRRL WC-3701 Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 241001619548 Treponema brennaborense Species 0.000 description 1
- 241000589907 Treponema bryantii Species 0.000 description 1
- 241001318046 Treponema endosymbiont of Eucomonympha sp. Species 0.000 description 1
- 241000037567 Treponema porcinum Species 0.000 description 1
- 241000589905 Treponema saccharophilum Species 0.000 description 1
- 241000520890 Treponema socranskii Species 0.000 description 1
- 241000690137 Treponema sp. C6A8 Species 0.000 description 1
- 241000296991 Treponema sp. JC4 Species 0.000 description 1
- 241000589903 Treponema succinifaciens Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000235017 Zygosaccharomyces Species 0.000 description 1
- 241001147790 [Clostridium] papyrosolvens Species 0.000 description 1
- 241000685809 [Clostridium] saccharogumia Species 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- -1 inhalant Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940115921 streptococcus equinus Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of Radix Angelicae Sinensis notoginseng composition, and Radix Angelicae Sinensis notoginseng composition is the drug for the treatment of with enteric flora disturbance related disease adjusting the purposes in enteric microorganism and its application in medicine preparation, the drug.
Description
Technical field
The invention belongs to medicines and health protection fields, and in particular to Radix Angelicae Sinensis Radix Notoginseng is improving and adjusting the use in enteric microorganism
On the way.
Background technique
Human body endosymbiosis a large amount of microorganisms, especially have about 100,000,000,000,000 bacterium of 1000-1150 kind in human body intestinal canal, be people
Body is most important " endogenous cycle border factor ", and number is 10 times or so of human body own cells number.Under normal circumstances, enteron aisle
Microorganism is in the ecological environment of a dynamic equilibrium, and normal flora not only plays not in digestion, immune and anti-virus aspect
Alternative effect, and the change of enteric microorganism is especially some chronic diseases with body health or disease and has
Extremely close relationship.Under contemporary society's environment, people's great work intensity, life stress is big, human body be chronically at it is various stress
State can frequently result in enteric microorganism imbalance, show as enteric microorganism on type, quantity, ratio and biological characteristics
Anomalous variation.Flora imbalance weakens the barrier function of enteron aisle by influencing body to the absorption of nutriment in turn again, into
One step aggravates disease, and forms a kind of vicious circle.Research confirmation, a variety of diseases of human body such as long-term diarrhea, constipation, enteritis
The morbidity of disease, digestive tract ulcer, diabetes, hypertension, hyperlipidemia, tumour etc. is all closely related with enteric microorganism.Although mesh
Actually the variation of preceding not clear intestinal microflora causes the generation of metabolism class disease, or the hair of metabolism class disease
The raw variation for resulting in intestinal microflora, but have any that can affirm: the composition by changing intestinal microflora,
The health of human body is had an impact, while help may also be provided to the treatment of certain diseases.Currently, enteric microorganism is recognized
For the possibility therapeutic targets for being a variety of diseases.
106620189 A of patent document CN provides a kind of method for improving enteric microorganism structure, and its is preparing medicine
Application during object, nutriment, health care product, food, beverage etc..The invention is used based on high throughput sequencing technologies and changeable
Amount statistical method has found the enteric bacteria monoid closely related with host metabolism, the bacterium as produced short chain fatty acids in enteron aisle
It is mostly beneficial bacterium, anti-inflammatory, protection intestinal barrier function, adjusting can be played by increasing the content of enteron aisle Short-Chain Fatty Acids
Body metabolism and it is immune the effects of.Short chain fatty acids producing strains include Blaw spy Bordetella, Allobaculum, general Bordetella, intend
Bacillus or Butyricimonas.It is mostly harmful bacteria that endotoxic bacterium is produced in enteron aisle, can be by increasing in enteron aisle
Content of toxins causes inflammation, damages intestinal barrier function, causes the effects of body metabolism and immune disorder.Generate endotoxic bacterium
Bacterium including Proteobacteria.
So far, the intestinal beneficial bacterium that scientist has found generally can be divided into three categories, including: lactobacillus class
(such as lactobacillus acidophilus, Lactobacillus casei, Lactobacillus Jensenii, Raman lactobacillus)；Bifidobacterium class (such as bifidobacterium longum, short
Bifidobacterium, oval Bifidobacterium, bifidobacterium thermophilum etc.)；Gram-positive cocci (such as streptococcus fecalis, galactococcus, intermediary's chain
Coccus etc.).
Human biology be it is dimerous by human genome and human microorganism's group, wherein human genome changes
Change is extremely difficult, but the change that microorganism is constituted in human body intestinal canal is relatively easy.High caloric diet, fast section at present
Life is played, so that the case where enteric microorganism disorder occurs in some people, removes nonemergency, majority can select to pass through diet
It is adjusted, existing research shows the micro- life of enteron aisle of the adjustable human body of the food of some Chinese medicines and some integration of drinking and medicinal herbs or animal
Object.The purposes in enteric microorganism is being adjusted as 105596445 A of patent document CN is related to root bark of tree peony radix paeoniae rubra, inventor, which studies, to be sent out
Existing, root bark of tree peony radix paeoniae rubra not only adjustable enteric microorganism, and no any side effect can take for a long time.For another example patent document
102987383 B of CN provides a kind of composition by integration of drinking and medicinal herbs food composition, and the composition can be used for balancing in main body
Enteric microorganism structure improves metabolic syndrome.
In the present invention, can inventor adjust enteric microorganism to Radix Angelicae Sinensis notoginseng composition and do correlative study.Radix Angelicae Sinensis
(Angelica sinensis), warm-natured, acrid-sweet flavor, return heart, liver, the spleen channel, root can be used as medicine, and be one of most common Chinese medicine.When
Return mainly containing sucrose, a variety of amino acid, volatile oil and n-butene, lactone, niacin, ferulic acid and half terpenoid, also contains
There are VitAVitE, volatile oil, arginine and several mineral materials, is usually used in benefiting blood and regulating blood circulation, menstruction regulating and pain relieving, moisturizing dryness and lubricating intestine.
Radix Notoginseng (Panax notoginseng) also known as pseudo-ginseng are araliaceae ginseng plant, are clinical common traditional Chinese medicines.Radix Notoginseng taste
Sweet, slight bitter, it is warm-natured, return liver, stomach, the heart, small intestinl channel, there is hemostasis, dissipate the stasis of blood, detumescence, analgesic, qi-restoratives, strong and other effects, cure mainly and cough up
Blood, traumatic hemorrhage, treating swelling and pain by traumatic injury etc., in recent years for treating coronary heart disease, diabetes, antianginal, antithrombotic etc., soap in Radix Notoginseng
Methods of glycosides is the main physiologically active ingredient of Radix Notoginseng.Patent document CN 201210569198.6, which is provided, a kind of prevents enteron aisle disease
The enema fluid and application thereof of disease, the enema fluid is made of Chinese medicine liquid, probiotics, synergistic component and physiological saline, the Chinese medicine
Liquid is prepared by Radix Notoginseng, Radix Angelicae Sinensis, the bletilla striata, charred RADIX SANGUISORBAE, the coptis by decocting method, and the enema fluid is preparing exedens rectum
Inflammation, constipation are applied in hematochezia preparation.It is excellent by the standby enema fluid therapeutic effect of this patent system, keep Intestinal Mucosal Injury in Patients Undergoing flora rapid
Restore normal.Although containing Radix Notoginseng and Radix Angelicae Sinensis in enema fluid simultaneously, since probiotics is added in enema fluid, so that Chinese medicine liquid
The effect played during restoring intestinal flora is unclear, and inventor does not probe into the Chinese medicines such as Radix Notoginseng and Radix Angelicae Sinensis individually yet and controlling
Pharmacological action during treatment.In order to avoid this defect, can inventor adjust intestines to Radix Notoginseng Radix Angelicae Sinensis composition in the present invention
Road flora has done careful research.
Summary of the invention
In the present invention, inventor presses down simultaneously the study found that Radix Angelicae Sinensis Radix Notoginseng can significantly improve the quantity of beneficial bacterium in enteron aisle
Enteric microorganism is adjusted in the quantity of harmful bacteria processed.It is had no at this stage about Radix Angelicae Sinensis Radix Notoginseng in terms of adjusting enteric microorganism
Research and report.
Therefore, a purpose of the invention is to provide a kind of Radix Angelicae Sinensis notoginseng composition；Another object of the present invention is to provide one
Kind Radix Angelicae Sinensis notoginseng composition is adjusting the purposes in enteric microorganism；The present invention, which a further object is, provides a kind of Radix Angelicae Sinensis Radix Notoginseng group
The application of object in medicine preparation is closed, the drug is the drug for the treatment of Yu enteric flora disturbance related disease.
The present invention provides a kind of Chinese medicine composition, and the traditional Chinese medicinal composition raw materials include Radix Angelicae Sinensis and Radix Notoginseng.
The present invention provides a kind of Chinese medicine composition, and the traditional Chinese medicinal composition raw materials are made of Radix Angelicae Sinensis and Radix Notoginseng.
In Chinese medicine composition of the present invention, the mass parts ratio of bulk pharmaceutical chemicals Radix Angelicae Sinensis and Radix Notoginseng is 1-99:99-1.
Preferably, the mass parts ratio of the bulk pharmaceutical chemicals Radix Angelicae Sinensis and Radix Notoginseng is 1-9:9-1.
In a preferred embodiment of this invention, Radix Angelicae Sinensis and the portion rate of Radix Notoginseng are 1:1,5:1,7:1,9:2.
Chinese medicine composition of the present invention is mixed with by the medicinal powder of bulk pharmaceutical chemicals or the extract of bulk pharmaceutical chemicals.
Preferably, further include acceptable auxiliary material in pharmacy in the Chinese medicine composition, the auxiliary material is selected from: carrying
Body, diluent, adhesive, lubricant, wetting agent.
Preferably, the dosage form of the Chinese medicine composition is selected from: tablet, capsule, pill, injection, inhalant, lozenge,
Suppository, emulsion, microemulsion, sub-micellar emulsion, nano particle, gelling agent, pulvis, suspended emulsion, cream, jelly, spray etc..
Preferably, the administration mode that the Chinese medicine composition can be taken is selected from: oral, enteron aisle to, be subcutaneously injected, muscle
Injection, intravenous injection, nasal-cavity administration, cutaneous penetration, sub-conjunctival administration, administration, eye socket administration, retrobulbar administration, view in eyeball
Nethike embrane administration, choroid administration, intrathecal injection etc..
The present invention provides a kind of Chinese medicine composition and is adjusting the purposes in enteric microorganism.
The purposes in enteric microorganism is being adjusted according to the Chinese medicine composition, can be in selective increase enteron aisle
The quantity of bacterium, the bacterium are selected from: bacillus genus (Paenibacillus), the thin end of the scroll Pseudomonas (Pedobacter), newborn bar
Pseudomonas (Lactobacillus), fusobacterium (Clostridium), Klebsiella (Klebsiella), streptomyces
(Streptomyces), Escherichia (Escherichia), Burkholderia (Burkholderia), gemma bar
Pseudomonas (Lysinibacillus), high temperature anaerobic Bacillus (Thermoanaerobacter), Porphyromonas Pseudomonas
(Porphyromonas), round bar Pseudomonas (Cyclobacterium), Bacteroides (Bacteroides), acinetobacter
(Acinetobacter), Treponema (Treponema), methane brevibacterium (Methanobrevibacter), thermophilic dioxy
Change carbon Cytophaga (Capnocytophaga), secondary bar Pseudomonas (Parabacteroides), sphingolipid Bacteriaceae
(Sphingobacteriaceae), staphylococcus (Staphylococcus), Sphingobacterium
(Sphingobacterium), rat-tail Pseudomonas (Muricauda), Flavobacterium (Flavobacterium), methane phase Pseudomonas
(methanogenic), Chryseobacterium (Chryseobacterium), fragrance Pseudomonas (Myroides), quasi- without branch acid Pseudomonas
(Amycolatopsis), Butyrivibrio (Butyrivibrio), Methylobacter (Methylobacterium), sulfurous acid
Bacillus (Sulfitobacter), purple bacillus (Porphyrobacter), Sphingomonas (Sphingomonas),
Rhizobium (Rhizobium), Selenomonas (Selenomonas), Cellulomonas (Fibrobacter), Aitken bacterium
Belong to (Eikenella), Saudi Bordetella (Sutterella), Bifidobacterium (Bifidobacterium), general Bordetella
One or more of (Prevotella) combination；
Preferably, the bacterium is selected from: bacillus genus, the thin end of the scroll Pseudomonas, lactobacillus, fusobacterium, streptomyces, porphin
Quinoline zygosaccharomyces, Bacteroides, Treponema, methane brevibacterium, pseudomonas, Flavobacterium, in Butyrivibrio
A combination of one or more；
It is furthermore preferred that the bacterium is selected from: Paenibacillus sp.RUD330, Paenibacillus
sp.UNC496MF、Paenibacillus sp.St-s、Pedobacter himalayensis、Pedobacter
nyackensis、Pedobacter ginsenosidimutans、Lactobacillus sp.UMNPBX12、
Lactobacillus vaginalis、Lactobacillus sp.UMNPBX5、Lactobacillus pontis、
Lactobacillus kimchicus、Lactobacillus panis、Lactobacillus mucosae、
Lactobacillus pentosiphilus、Lactobacillus sp.UMNPBX8、Lactobacillus
sp.Marseille-P3519、Clostridium sp.Bc-iso-3、Clostridium sp.HMSC19C08、
[Clostridium]saccharogumia、Clostridium sp.mt5、[Clostridium]papyrosolvens、
Clostridium baratii、Clostridium septicum、Clostridium sp.HMSC19B04、Clostridium
saudiense、Clostridium sp.HMSC19D07、Clostridium cellulovorans、Clostridium
taeniosporum、Clostridium cochlearium、Clostridium botulinum、Clostridium
bornimense、Clostridium hydrogeniformans、Clostridium neonatale、Clostridium
sp.KNHs209、Clostridium chauvoei、Clostridium sp.SS2/1、Clostridium uliginosum、
Clostridium grantii、Clostridium sp.USBA 49、Clostridium tetanomorphum、
Clostridium celatum、Clostridium collagenovorans、Clostridium ventriculi、
Clostridium cavendishii、Clostridium gasigenes、Clostridium gasigenes、
Clostridium sp.ND2、Clostridium sp.DSM 8431、Clostridium frigidicarnis、
Streptomyces sp.NRRL WC-3701、Streptomyces sp.NRRL F-6676、Streptomyces
rimosus、Streptomyces sp.NRRL F-5639、Streptomyces sp.AA4、Porphyromonas sp.COT-
108 OH2963、Porphyromonas canoris、Porphyromonas gingivicanis、Porphyromonas
asaccharolytica、Porphyromonas sp.COT-108 OH1349、Porphyromonas sp.KLE 1280、
Porphyromonas cangingivalis、Porphyromonas gingivalis、Bacteroides sp.3_1_23、
Bacteroides sp.3_1_19、Bacteroides gallinarum、Bacteroides sp.3_1_40A、
Bacteroides sp.3_2_5、Bacteroides sp.AR29、Bacteroides sp.3_1_13、Bacteroides
caecimuris、Bacteroides pyogenes、Bacteroides sp.14(A)、Bacteroides
cellulosilyticus、Bacteroides sp.An269、Bacteroides eggerthii、Bacteroides
sp.Marseille-P2653、Bacteroides fragilis、Bacteroides xylanisolvens、Bacteroides
sp.2_1_16、Bacteroides salyersiae、Treponema bryantii、Treponema sp.C6A8、
Treponema succinifaciens、Treponema sp.JC4、Treponema porcinum、Treponema
saccharophilum、Treponema brennaborense、Treponema socranskii、Treponema
endosymbiont of Eucomonympha sp.、Methanobrevibacter sp.A27、Methanobrevibacter
sp.YE315、Methanobrevibacter gottschalkii、Methanobrevibacter millerae、
Methanobrevibacter oralis、Methanobrevibacter sp.87.7、Methanobrevibacter
smithii、Methanobrevibacter olleyae、Methanobrevibacter sp.A54、
Methanobrevibacter arboriphilus、Methanobrevibacter ruminantium、
Methanobrevibacter filiformis、Methanobrevibacter wolinii、Methanobrevibacter
curvatus、Pseudomonas protegens、Pseudomonas otitidis、Pseudomonas sp.Bc-h、
Flavobacterium sp.A45、Flavobacterium johnsoniae、Flavobacterium frigoris、
Flavobacterium sp.316、Flavobacterium marinum、Flavobacterium akiainvivens、
Flavobacterium indicum、Flavobacterium terrigena、Butyrivibrio sp.NC2002、
Butyrivibrio sp.WCE2006、Butyrivibrio sp.AE2005、Butyrivibrio sp.INlla14、
Butyrivibrio sp.LC3010、Butyrivibrio sp.AD3002、Butyrivibrio sp.YAB3001、
Butyrivibrio sp.VCD2006、Butyrivibrio sp.NC3005、Butyrivibrio crossotus、
The combination of one or more of Butyrivibrio sp.NC2007.
The purposes in enteric microorganism is being adjusted according to the Chinese medicine composition, can be in selective inhibition enteron aisle
The quantity of bacterium, the bacterium are selected from: Si Shi methane spherical shape Pseudomonas (Methanosphaera), enterococcus spp
(Enterococcus), shigella (Shigella), secondary bar Pseudomonas (Parabacteroides), Enterobacter
(Enterobacter), streptococcus (Streptococcus), Helicobacterium (Helicobacter), anaerobism Ureaplasma
(Anaeroplasma), the combination of one or more of Coprecoccus (Coprococcus)；
Preferably, the bacterium is selected from: Si Shi methane spherical shape Pseudomonas, enterococcus spp, shigella, secondary bar Pseudomonas,
The combination of one or more of Enterobacter, streptococcus, Helicobacterium；
It is furthermore preferred that the bacterium is selected from: Methanosphaera cuniculi, Enterococcus
sp.HMSC074F07、Shigella sp.PAMC 28760、Parabacteroides sp.YL27、Parabacteroides
sp.D25、Enterobacter sp.BIDMC94、Streptococcus sp.HMSC076H08、Streptococcus
sp.HMSC056C01、Streptococcus sp.HMSC034E12、Streptococcus sp.HMSC056D01、
Streptococcus sp.CM7、Streptococcus equinus、Streptococcus agalactiae、
Streptococcus sp.HMSC064H02、Streptococcus sp.HMSC078E08、Streptococcus
sp.HMSC071H03、Streptococcus sp.HMSC072G02、Streptococcus sp.HMSC034B04、
Streptococcus sp.HMSC078E03、Streptococcus sp.HMSC074F09、Streptococcus
sp.GMD6S、Streptococcus sp.HMSC076H07、Helicobacter himalayensis、Helicobacter
fennelliae、Helicobacter bilis、Helicobacter macacae、Helicobacter sp.CLO-3、
The combination of one or more of Helicobacter saguini, Helicobacter magdeburgensis.
The purposes in enteric microorganism is being adjusted according to the Chinese medicine composition, can be in selective inhibition enteron aisle
The quantity of virus, the virus are selected from: streptococcus virus (Streptococcus virus), enterococcus bacteriophage
(Enterococcus phage), Bacillus acidi lactici bacteriophage (Lactobacillus phage), Bacillus acidi lactici prophage
One or more of (Lactobacillus prophage), enterobacteria bacteriophage (Enterobacteria phage)
Combination；
Preferably, the virus is selected from: one or both of streptococcus virus, enterococcus bacteriophage；
It is furthermore preferred that the virus is selected from: Enterococcus phage vB_EfaP_IME195, Streptococcus
The combination of one or more of virus7201, Streptococcus virus C1.
The present invention provides a kind of application of Chinese medicine composition in medicine preparation, the drug be treat it is disorderly with intestinal flora
The drug of random related disease, it is preferred that the disease is selected from: long-term diarrhea, constipation, obesity, food hypersenstivity, pancreatitis, liver
It includes gestational period glycosuria that damage, intestinal inflammatory, which include Crohn disease, irritable bowel syndrome, digestive tract ulcer, kidney stone, diabetes,
Disease, rheumatoid arthritis, Behcet's disease, cardiovascular disease, cranial vascular disease include apoplexy, tumour, paralysis, eye disease, multiple
Sclerosis, ankylosing spondylitis, parkinsonism, anxiety, self-closing disease, depression, chronic fatigue syndrome.
It is of the present invention to be classified as angelica powder or angelica extract, it is preferred that described to be classified as angelica extract.
In a preferred embodiment of the present invention, the angelica powder is plantation 3 years or more summers, late autumn or early winters
Angelica root preparation powder.
A kind of preparation method of angelica powder is the following steps are included: (1) Radix Angelicae Sinensis cleans immersion, and (2) slice, (3) are dry, (4)
It crushes, (5) packaging.
Preferably, it is 10-30min that Radix Angelicae Sinensis, which cleans soaking time, in the step (1)；It is furthermore preferred that the soaking time
For 20-25min.
Preferably, Radix Angelicae Sinensis is cut into the piece of 1-2mm in the step (2).
Preferably, drying mode is selected from the step (3): being dried in the shade, is dried or low temperature drying, so that angelica surface moisture
≤ 0.5%.
Preferably, when channel tropism is crushed to 200-1200 mesh in the step (4)；It is furthermore preferred that Radix Angelicae Sinensis in the step (4)
It is crushed to 800-1200 mesh.
Preferably, it is vacuum-packed after angelica powder being carried out sterilization treatment in the step (5).
In a preferred embodiment of the present invention, the angelica extract be 3 years or more summers of plantation, late autumn or
The Angelica roots of early winter.
The extracting method is selected from: solvent extraction method, percolation, decocting method, circumfluence method, continuous backflow method, ultrasonic extraction
Method, supercritical fluid extraction, steam distillation, sublimed method, resin adsorption partition method, gel chromatography separation method；
Preferably, the extracting method is selected from: solvent extraction method, decocting method, resin adsorption partition method.
A kind of preparation method of angelica extract the following steps are included:
(1) by Radix Angelicae Sinensis raw material stoving, Radix Angelicae Sinensis coarse powder is crushed to obtain；
(2) Radix Angelicae Sinensis coarse powder solvent extraction carries out that concentrate is concentrated under reduced pressure to obtain after filtering；
(3) concentrate is crossed adsorption column to elute, first with purifying water washing, removes impurity, must be eluted with ethanol elution
Liquid；
(4) eluent, decolorization is concentrated under reduced pressure, purification is concentrated under reduced pressure into medicinal extract, obtains angelica extract after dry.
Preferably, the temperature toasted in the step (1) is 90-120 DEG C, and Radix Angelicae Sinensis raw material is crushed to 10-80 mesh.
Preferably, solvent is selected from the step (2): n,N-Dimethylformamide, acetic acid, methylene chloride, methanol, second
Alcohol, isopropanol, the tert-butyl alcohol, acetonitrile or acetone；It is furthermore preferred that the solvent is selected from: 50%-80% ethanol solution.
Preferably, absorption column packing is selected from the step (3): HPD series, ADS series, HZ series, XAD series and D
One of serial macroreticular resin filler or more than one combination；It is furthermore preferred that the absorption column packing is selected from: HPD100,
One of HZ18 and D101 or more than one combination.
Preferably, drying mode is selected from the step (4): spray drying, vacuum drying, freeze-drying, near-infrared are dry
One of dry and microwave drying or more than one combination；It is more preferably dried in vacuo, drying temperature is 30-50 DEG C.
Radix Notoginseng of the present invention is Radix Notoginseng powder or Notogineng Extract, it is preferred that the Radix Notoginseng is Notogineng Extract.
Radix Notoginseng powder of the present invention can be or mixtures thereof the root of Radix Notoginseng, stem, leaf, flower and help powder for raw material crushing,
Since Roots of Panax Notoginseng medical value is best, in a preferred embodiment of the present invention, the Radix Notoginseng powder is Roots of Panax Notoginseng preparation
Powder.
The following steps are included: (1) Radix Notoginseng cleans immersion, (2) steam a kind of preparation method of Radix Notoginseng powder, (3) drying, (4)
It crushes, (5) packaging.
Preferably, it is 10-30min that Radix Notoginseng, which cleans soaking time, in the step (1)；It is furthermore preferred that the soaking time
For 20-25min.
Preferably, steaming temperature is 100-150 DEG C in the step (2), and steaming pressure is 180-200pa, steaming time
For 60-90min；It is furthermore preferred that the steaming temperature is 120-140 DEG C, steaming pressure is 190-200pa, steaming time 70-
80min。
Preferably, drying temperature is 100-120 DEG C in the step (3)；It is furthermore preferred that the drying temperature is 110-
120℃。
Preferably, Radix Notoginseng is crushed to 200-1200 mesh in the step (4)；It is furthermore preferred that Radix Notoginseng in the step (4)
It is crushed to 800-1200 mesh.
Preferably, it is vacuum-packed after Radix Notoginseng powder being carried out sterilization treatment in the step (5).
Notogineng Extract of the present invention can be or mixtures thereof the root of Radix Notoginseng, stem, leaf, flower and extract preparation for raw material
It obtains.Since Roots of Panax Notoginseng medical value is best, in a preferred embodiment of the present invention, the Notogineng Extract is Radix Notoginseng
Root extract.
The extracting method is selected from: solvent extraction method, percolation, decocting method, circumfluence method, continuous backflow method, ultrasonic extraction
Method, supercritical fluid extraction, steam distillation, sublimed method, resin adsorption partition method, gel chromatography separation method；
Preferably, the extracting method is selected from: solvent extraction method, decocting method, resin adsorption partition method.
A kind of preparation method of Notogineng Extract the following steps are included:
(1) by Radix Notoginseng raw material stoving, Radix Notoginseng coarse powder is crushed to obtain；
(2) Radix Notoginseng coarse powder solvent extraction carries out that Radix Notoginseng concentrate is concentrated under reduced pressure to obtain after filtering；
(3) Radix Notoginseng concentrate is crossed adsorption column to elute, first with purifying water washing, removes impurity, obtained with ethanol elution
Eluent；
(4) eluent, decolorization is concentrated under reduced pressure, purification is concentrated under reduced pressure into medicinal extract, obtains Notogineng Extract after dry.
Preferably, the temperature toasted in the step (1) is 90-120 DEG C, and Radix Notoginseng raw material is crushed to 10-80 mesh.
Preferably, solvent is selected from the step (2): n,N-Dimethylformamide, acetic acid, methylene chloride, methanol, second
Alcohol, isopropanol, the tert-butyl alcohol, acetonitrile or acetone；It is furthermore preferred that the solvent is selected from: 50%-80% ethanol solution.
Preferably, absorption column packing is selected from the step (3): HPD series, ADS series, HZ series, XAD series and D
One of serial macroreticular resin filler or more than one combination；It is furthermore preferred that the absorption column packing is selected from: HPD100,
One of HZ18 and D101 or more than one combination.
Preferably, drying mode is selected from the step (4): spray drying, vacuum drying, freeze-drying, near-infrared are dry
One of dry and microwave drying or more than one combination；It is more preferably dried in vacuo, drying temperature is 30-50 DEG C.
Detailed description of the invention
The enteric microorganism species that Fig. 1 Radix Angelicae Sinensis and notoginseng composition change
Specific embodiment
The preparation of 1 angelica powder of embodiment
It selects the higher angelica root of medical value to be prepared, the angelica root of harvesting is poured into and impregnates 20min in cold water, clearly
Wash clean, Radix Angelicae Sinensis are cut into the piece of 2mm, are put into low temperature drying case and are dried, temperature range: 30-40 DEG C, humidity range: 10-
20%RH, so that angelica surface moisture≤0.5%, inputs in pulverizer in time while hot with the Radix Angelicae Sinensis that will be dried and is crushed,
900 mesh are crushed to, are vacuum-packed after the angelica powder for being ground into powder is carried out sterilization treatment.
2 ethanol immersion of embodiment prepares angelica extract
The higher angelica root of medical value is selected to be prepared, by angelica root raw material stoving, baking temperature is 90 DEG C, is crushed
Radix Angelicae Sinensis coarse powder is obtained to 20 mesh, Radix Angelicae Sinensis coarse powder is extracted 3 times with 80% ethanol solution, after extracting solution filtering carries out that Radix Angelicae Sinensis is concentrated under reduced pressure to obtain
Radix Angelicae Sinensis concentrate is crossed adsorption column and eluted by concentrate, and absorption column packing is HPD100, first with purifying water washing, removes impurity elimination
Matter, then eluent is obtained with 60%, 70%, 80% ethanol elution, eluent, decolorization is concentrated under reduced pressure, purification is concentrated under reduced pressure into
Medicinal extract obtains angelica extract after freeze-dried.
3 water boiling method of embodiment prepares angelica extract
It selects the higher angelica root of medical value to extract, weighs 100g angelica root, set in the pan-fried device of suitable volume, add
Water about 600ml submerges medicinal material 1h, heats 0.5h after boiling.Fried liquid is separated, the dregs of a decoction carry out secondary decoction, fried liquid and first time
Fried liquid mixing, measures volume with graduated cylinder, further boils fried liquid if volume is more than 600ml and be concentrated into about 600ml, reach
Fried liquid is vacuum-packed after to respective volume, is filled in 7-8 pouch, 4 DEG C is put into and saves for use.
The preparation of 4 Radix Notoginseng powder of embodiment
It selects the higher Roots of Panax Notoginseng of medical value to be prepared, the Roots of Panax Notoginseng of harvesting is poured into and impregnates 20min in cold water, it will
Soil is poured into steamer after eluriating completely and is steamed, and steaming temperature is 120 DEG C, and steaming pressure is 190pa, and steaming time is
70min.The Roots of Panax Notoginseng steamed is dried in drying box, drying temperature is 110 DEG C, drying time 3h, with will dry
Dry Radix Notoginseng inputs in pulverizer in time crushed while hot, is crushed to 900 mesh, the Radix Notoginseng powder for being ground into powder is sterilized
It is vacuum-packed after processing.
5 ethanol immersion of embodiment prepares Notogineng Extract
The higher Roots of Panax Notoginseng of medical value is selected to be prepared, by Roots of Panax Notoginseng raw material stoving, baking temperature is 90 DEG C, is crushed
Radix Notoginseng coarse powder is obtained to 20 mesh, Radix Notoginseng coarse powder is extracted 3 times with 80% ethanol solution, after extracting solution filtering carries out that Radix Notoginseng is concentrated under reduced pressure to obtain
Radix Notoginseng concentrate is crossed adsorption column and eluted by concentrate, and absorption column packing is HPD100, first with purifying water washing, removes impurity elimination
Matter, then eluent is obtained with 60%, 70%, 80% ethanol elution, eluent, decolorization is concentrated under reduced pressure, purification is concentrated under reduced pressure into
Medicinal extract obtains Notogineng Extract after freeze-dried.
6 water boiling method of embodiment prepares Notogineng Extract
It selects the higher Roots of Panax Notoginseng of medical value to extract, weighs 100g Roots of Panax Notoginseng, set in the pan-fried device of suitable volume, add
Water about 600ml submerges medicinal material 1h, heats 0.5h after boiling.Fried liquid is separated, the dregs of a decoction carry out secondary decoction, fried liquid and first time
Fried liquid mixing, measures volume with graduated cylinder, further boils fried liquid if volume is more than 600ml and be concentrated into about 600ml, reach
Fried liquid is vacuum-packed after to respective volume, is filled in 7-8 pouch, 4 DEG C is put into and saves for use.
The preparation of embodiment 7 Radix Angelicae Sinensis and notoginseng composition
Angelica extract is respectively adopted solvent extraction method with Notogineng Extract and extracts, and resin adsorption partition method is divided
From, it is obtained after freeze-drying, respectively takes 1 part to be sufficiently mixed angelica extract and Notogineng Extract, the group of obtained Radix Angelicae Sinensis and Radix Notoginseng
Close object.
Influence of the 8 Radix Angelicae Sinensis notoginseng composition of embodiment to enteric microorganism
This experiment uses monkey as experimental subjects to test, and experimental drug is respectively the Radix Angelicae Sinensis and three prepared according to embodiment 7
Seven composition, administration mode are intranasal gastric infusion, and stomach-filling is continuous 14 days once a day.Daily in acquisition stomach-filling 14 days,
Each 1 day excrement before and after stomach-filling.Experimental standard is as follows: monkey raising is executed according to non-human primate experimental animal feeding standard, often
8 points of its morning is rinsed cage for animal bottom, and a stainless (steel) wire is put into cage for animal bottom, waits monkey voluntarily defecation, row later
Monkey ID is checked after an action of the bowels, is taken pictures to excrement, is acquired excrement using urine collector, is paid attention to avoiding contacting with wire side in collection process
Excrement, be put into -80 DEG C of refrigerators later and save.
The extraction of DNA is extracted using strength faeces DNA extracts kit (Qiagen, USA), each sample extraction
100ng DNA is crushed the DNA fragmentation that 300-400bp is made in instrument with non-contact type ultrasonic, uses high-flux sequence platform library
Building orientation optimization kit VAHTS Nano DNA Library Prep Kit for Illumina (Vazyme, China) into
Row sequencing, sequencing depth is up to 3,000 ten thousand -5 thousand ten thousand each samples, to each sequencing reading progress quality control, for non-source of people sequence
Column are analyzed using Kraken and Bracken, and using customized database as reference, this database is included in 2017 12
Bacterium, archeobacteria, virus, fungi and protozoic genome all in RefSeq before the moon 22.
Experimental result is as shown in table 1, finds after counting to experimental result, and the composition of Radix Angelicae Sinensis and Radix Notoginseng is micro- to enteron aisle
The influence of biology includes the quantity of some bacteriums in the increase enteron aisle of selectivity, while inhibiting the number of other bacterium in enteron aisle
Amount and some viruses in enteron aisle is inhibited to play a role.
The enteric microorganism species that 1 Radix Angelicae Sinensis of table and notoginseng composition change
Claims (11)
1. a kind of Chinese medicine composition, the traditional Chinese medicinal composition raw materials include Radix Angelicae Sinensis and Radix Notoginseng.
2. Chinese medicine composition according to claim 1, which is characterized in that the quality of Radix Angelicae Sinensis and Radix Notoginseng in the bulk pharmaceutical chemicals
Portion rate is 1-99:99-1.
3. Chinese medicine composition according to claim 2, which is characterized in that the quality of Radix Angelicae Sinensis and Radix Notoginseng in the bulk pharmaceutical chemicals
Portion rate is 1-9:9-1.
4. a kind of Chinese medicine composition described in claim 1 is adjusting the purposes in enteric microorganism.
5. Chinese medicine composition according to claim 4 is adjusting the purposes in enteric microorganism, which is characterized in that described
The quantity for increasing bacterium in enteron aisle that enteric microorganism is selectivity is adjusted, the bacterium is selected from: bacillus genus
(Penibacillus), the thin end of the scroll Pseudomonas (Pedobacter), lactobacillus (Lactobacillus), fusobacterium
(Clostridium), Klebsiella (Klebsiella), streptomyces (Streptomyces), Escherichia
(Escherichia), Burkholderia (Burkholderia), bacillus (Lysinibacillus), high temperature are detested
Oxygen Bacillus (Thermoanaerobacter), Porphyromonas Pseudomonas (Porphyromonas), round bar Pseudomonas
(Cyclobacterium), Bacteroides (Bacteroides), acinetobacter (Acinetobacter), Treponema
(Treponema), methane brevibacterium (Methanobrevibacter), capnocytophaga category
(Capnocytophaga), secondary bar Pseudomonas (Parabacteroides), sphingolipid Bacteriaceae (Sphingobacteriaceae), Portugal
Grape Coccus (Staphylococcus), Sphingobacterium (Sphingobacterium), rat-tail Pseudomonas (Muricauda),
Flavobacterium (Flavobacterium), methane phase Pseudomonas (methanogenic), Chryseobacterium
(Chryseobacterium), fragrance Pseudomonas (Myroides), quasi- without branch acid Pseudomonas (Amycolatopsis), Butyrivibrio
(Butyrivibrio), Methylobacter (Methylobacterium), sulfurous acid Bacillus (Sulfitobacter), purple bar
Pseudomonas (Porphyrobacter), Sphingomonas (Sphingomonas), rhizobium (Rhizobium), moon shape list
Born of the same parents Pseudomonas (Selenomonas), Cellulomonas (Fibrobacter), Eikenella (Eikenella), Saudi Bordetella
(Sutterella), one or both of Bifidobacterium (Bifidobacterium), general Bordetella (Prevotella) with
On combination.
6. Chinese medicine composition according to claim 5 is adjusting the purposes in enteric microorganism, which is characterized in that described thin
Bacterium is selected from: bacillus genus, the thin end of the scroll Pseudomonas, lactobacillus, fusobacterium, streptomyces, Porphyromonas Pseudomonas, Bacteroides,
The group of one or more of Treponema, methane brevibacterium, pseudomonas, Flavobacterium, Butyrivibrio
It closes.
7. Chinese medicine composition according to claim 4 is adjusting the purposes in enteric microorganism, which is characterized in that described
The quantity for inhibiting bacterium in enteron aisle that enteric microorganism is selectivity is adjusted, the bacterium is selected from: Si Shi methane spherical shape Pseudomonas
(Methanosphaera), enterococcus spp (Enterococcus), shigella (Shigella), secondary bar Pseudomonas
(Parabacteroides), Enterobacter (Enterobacter), streptococcus (Streptococcus), Helicobacterium
(Helicobacter), one or both of anaerobism Ureaplasma (Anaeroplasma), Coprecoccus (Coprococcus) with
On combination.
8. Chinese medicine composition according to claim 7 is adjusting the purposes in enteric microorganism, which is characterized in that described thin
Bacterium is selected from: Si Shi methane spherical shape Pseudomonas, enterococcus spp, shigella, secondary bar Pseudomonas, Enterobacter, streptococcus, screw rod
The combination of one or more of Pseudomonas.
9. Chinese medicine composition according to claim 4 is adjusting the purposes in enteric microorganism, which is characterized in that described
Quantity viral in the inhibition enteron aisle that enteric microorganism is selectivity is adjusted, the virus is selected from: streptococcus virus
(Streptococcus virus), enterococcus bacteriophage (Enterococcus phage), Bacillus acidi lactici bacteriophage
(Lactobacillus phage), Bacillus acidi lactici prophage (Lactobacillus prophage), enterobacteria bacteriophage
The combination of one or more of (Enterobacteria phage).
10. a kind of application of Chinese medicine composition described in claim 1 in medicine preparation, the drug is treatment and enterobacteriaceae
The drug of group's disorder related disease.
11. the application of Chinese medicine composition according to claim 10 in medicine preparation, which is characterized in that the disease choosing
From: long-term diarrhea, constipation, obesity, food hypersenstivity, pancreatitis, hepatic injury, intestinal inflammatory, irritable bowel syndrome, alimentary canal are burst
Ulcer, kidney stone, diabetes, rheumatoid arthritis, Behcet's disease, cardiovascular disease, cranial vascular disease, tumour, paralysis, eye disease,
Multiple sclerosis, ankylosing spondylitis, parkinsonism, anxiety, self-closing disease, depression, chronic fatigue syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810400384.4A CN110403966A (en) | 2018-04-28 | 2018-04-28 | Radix Angelicae Sinensis notoginseng composition and its purposes in adjusting enteric microorganism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810400384.4A CN110403966A (en) | 2018-04-28 | 2018-04-28 | Radix Angelicae Sinensis notoginseng composition and its purposes in adjusting enteric microorganism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110403966A true CN110403966A (en) | 2019-11-05 |
Family
ID=68356931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810400384.4A Pending CN110403966A (en) | 2018-04-28 | 2018-04-28 | Radix Angelicae Sinensis notoginseng composition and its purposes in adjusting enteric microorganism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110403966A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110916192A (en) * | 2019-11-25 | 2020-03-27 | 垒途智能教科技术研究院江苏有限公司 | Probiotic mineral powder capable of preventing and treating autism of children and teenagers and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103007046A (en) * | 2012-12-25 | 2013-04-03 | 浙江农林大学 | Coloclysis liquid capable of preventing intestinal diseases, and application thereof |
-
2018
- 2018-04-28 CN CN201810400384.4A patent/CN110403966A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103007046A (en) * | 2012-12-25 | 2013-04-03 | 浙江农林大学 | Coloclysis liquid capable of preventing intestinal diseases, and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| LEI CHEN等: "Dietary saponins from four popular herbal tea exert prebiotic-like effects on gut microbiota in C57BL/6 mice", 《JOURNAL OF FUNCTIONAL FOODS》 * |
| 曹俊敏等: "茯苓等4种中药扶植实验小鼠肠道正常菌群生长及其机理的初步研究", 《中华中医药学刊》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110916192A (en) * | 2019-11-25 | 2020-03-27 | 垒途智能教科技术研究院江苏有限公司 | Probiotic mineral powder capable of preventing and treating autism of children and teenagers and application thereof |
| CN110916192B (en) * | 2019-11-25 | 2021-04-13 | 垒途智能教科技术研究院江苏有限公司 | Probiotic mineral powder capable of preventing and treating autism of children and teenagers and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110403965A (en) | Radix Angelicae Sinensis is adjusting the purposes in enteric microorganism | |
| CN110404076A (en) | Radix Notoginseng is adjusting the purposes in enteric microorganism | |
| Babu et al. | Phytochemicals, polyphenols, prebiotic effect of Ocimum sanctum, Zingiber officinale, Piper nigrum extracts | |
| WO2012097579A1 (en) | Pharmaceutical composition for treating melasma and preparation method therefor | |
| CN110522789A (en) | Radix Astragali is adjusting the purposes in enteric microorganism | |
| CN105748622A (en) | Probiotic fermented traditional Chinese medicine composition for spasmolysis and analgesia and preparation method and application thereof | |
| CN111870568B (en) | Anti-allergy itching-relieving plant composition and preparation method and application thereof | |
| Akbar et al. | Glycyrrhiza glabra L.(Fabaceae/Leguminosae) (Syns.: G. glandulifera Waldst. & Kit.; G. hirsuta Pall.; G. pallida Boiss. & Noe; G. violacea Boiss. & Noe) | |
| CN110522843A (en) | Rhizoma polygonati is adjusting the purposes in enteric microorganism | |
| CN111973651A (en) | Use of licorice root for treating diseases related to intestinal flora disturbance | |
| CN103451084B (en) | Hangover liver protection vinegar and preparation method and application thereof | |
| CN110613746A (en) | Astragalus membranaceus, rhizoma polygonati and angelica sinensis composition and application thereof in regulating intestinal microorganisms | |
| CN103393908B (en) | Product for treating systemic lupus erythematosus and rheumatism and preparation method thereof | |
| CN110403966A (en) | Radix Angelicae Sinensis notoginseng composition and its purposes in adjusting enteric microorganism | |
| CN110575507A (en) | Application of coix seed in regulating intestinal microorganisms | |
| CN111821329A (en) | Application of ginseng in regulating intestinal microorganisms | |
| CN110522860A (en) | Rhizoma imperatae is adjusting the purposes in enteric microorganism | |
| CN110613849A (en) | Traditional Chinese medicine composition and application thereof in regulating intestinal microorganisms | |
| CN110522797A (en) | Charred RADIX ET RHIZOMA RHEI is adjusting the purposes in enteric microorganism | |
| CN110613802A (en) | Rhizoma imperatae, rhubarb and charcoal pseudo-ginseng composition and application thereof in regulating intestinal microorganisms | |
| CN112022904A (en) | Application of fructus forsythiae in treating diseases related to intestinal flora disorder | |
| CN111116708A (en) | Compound, traditional Chinese medicine probiotic fermentation product and application of compound and traditional Chinese medicine probiotic fermentation product in preparation of medicine or health-care product with effects of dispelling effects of alcohol and protecting stomach | |
| CN111743952A (en) | Use of rehmanniae radix in regulating intestinal microorganism | |
| CN111904989A (en) | Application of radix bupleuri in regulating intestinal microorganisms | |
| KR20190049162A (en) | Functional fermented composition for anti-obesity, manufacturing method thereof, and food comprsing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191105 |
|
| RJ01 | Rejection of invention patent application after publication |